DISCLAIMER: This content is for educational and informational purposes only and is intended for medical professionals. It does not constitute medical advice, diagnosis, or treatment strategies for specific patients. Clinical judgment is essential, and consultation with a nephrologist is strongly recommended for suspected renal pathology. Follow institutional protocols and local guidelines.

---

RPGN (Rapidly Progressive Glomerulonephritis) vs. CKD (Chronic Kidney Disease)

Overview

Definition

• RPGN: A clinical syndrome characterized by a rapid loss of renal function (usually a 50% decline in Glomerular Filtration Rate [GFR] within 3 months) accompanied by extensive glomerular crescent formation (>50% of glomeruli) on biopsy. It is a medical emergency.
• CKD: Abnormalities of kidney structure or function, present for >3 months, with implications for health. Criteria include either GFR <60 mL/min/1.73m² or markers of kidney damage (e.g., albuminuria, electrolyte abnormalities due to tubular disorders, structural abnormalities).

Epidemiology

• RPGN: Rare. Incidence of ANCA-associated vasculitis (a major cause) is approx. 10–20 per million/year. Peak incidence in adults 50–70 years, though Post-streptococcal GN is common in children.
• CKD: Common public health issue. Global prevalence estimated at 10–13%. In the US, approx. 15% of adults have CKD. Prevalence increases significantly with age (>35% in adults >70 years).

Classification

• RPGN (Immunological Classification):
  • Type 1: Anti-GBM disease (Goodpasture’s). Linear IgG deposition.
  • Type 2: Immune-complex mediated (e.g., Lupus nephritis, IgA nephropathy, Post-infectious). Granular deposition.
  • Type 3: Pauci-immune (ANCA-associated vasculitis: GPA, MPA, EGPA). Little/no staining.
• CKD (KDIGO Staging):
  • G-Stage (GFR): G1 (>90), G2 (60-89), G3a (45-59), G3b (30-44), G4 (15-29), G5 (<15).
  • A-Stage (Albuminuria): A1 (<30 mg/g), A2 (30-300 mg/g), A3 (>300 mg/g).

Pathophysiology

Mechanism

• RPGN: Severe glomerular capillary wall injury leads to gaps in the basement membrane → leakage of plasma proteins and inflammatory cells (macrophages, T-cells) into Bowman's space → proliferation of parietal epithelial cells and fibrin deposition → Crescent formation → compression of the glomerular tuft → rapid tubulointerstitial fibrosis and permanent loss of nephrons.
• CKD: Initial insult leads to nephron loss → maladaptive hyperfiltration and hypertrophy of remaining viable nephrons → increased intraglomerular pressure → glomerulosclerosis and tubulointerstitial fibrosis. Final common pathway regardless of etiology is fibrosis and atrophy.

Risk Factors

• RPGN: Genetic predisposition (HLA types), exposure to silica/solvents (ANCA), recent infections (Streptococcus, Staphylococcus), drugs (hydralazine, propylthiouracil, penicillamine, cocaine/levamisole), malignancy.
• CKD: Diabetes mellitus (leading cause), Hypertension, cardiovascular disease, obesity, older age, family history, acute kidney injury (AKI) history, smoking, potentially nephrotoxic drugs (chronic NSAID use).

Protective Factors

• RPGN: Early recognition and prompt immunosuppression.
• CKD: RAS inhibition (ACEi/ARB), SGLT2 inhibitors, blood pressure control, glycemic control.

Clinical Presentation

Signs and Symptoms

Feature	RPGN (Acute/Subacute)	CKD (Chronic/Insidious)
Onset	Days to weeks (rarely months)	Years to decades
Urinary	Gross hematuria ("tea-colored"), oliguria	Nocturia, polyuria (early), foam (proteinuria)
Systemic	Fever, malaise, arthralgias, weight loss	Fatigue, anorexia, pruritus, cold intolerance
Respiratory	Hemoptysis/dyspnea (if Pulmonary-Renal Syndrome)	Dyspnea (fluid overload/anemia)
Volume Status	Acute edema, hypertension (rapid onset)	Chronic edema, resistant hypertension

• Cardinal Features (RPGN): Nephritic syndrome (hematuria, RBC casts, hypertension, sub-nephrotic proteinuria) + Rapid rise in Creatinine.
• Early Signs (CKD): Asymptomatic; discovered incidentally via lab work (elevated Cre, proteinuria).
• Advanced Signs (CKD): Uremic fetor, asterixis, encephalopathy, pericardial friction rub.

Physical Examination

• Inspection:
  • RPGN: Palpable purpura (vasculitis), track marks (endocarditis-associated), pallor.
  • CKD: Sallow/yellowish skin pigmentation, excoriations (uremic pruritus), Lindsay's nails (half-and-half nails).
• Palpation/Auscultation:
  • RPGN: Lung crackles (hemorrhage/edema), joint tenderness/swelling.
  • CKD: AV fistula scars, peripheral neuropathy (decreased sensation), displaced PMI (LVH).

Diagnostic Approach

History Taking

• Key Questions:
  • Timeline: "When was your last normal kidney blood test?" (Crucial differentiator).
  • Review of Systems: "Any coughing up blood? (Pulmonary-renal syn)", "Sinus congestion/bloody crusts? (GPA)", "Joint pain?", "Rashes?".
  • Exposures: Recent infections (skin/throat), new medications, illicit drug use.
• Red Flags: Hemoptysis, rapid oliguria/anuria, purpuric rash, neurological deficits (mononeuritis multiplex).

Laboratory Tests

• Urinalysis & Sediment (The "Liquid Biopsy"):
  • RPGN: "Active" sediment. Dysmorphic RBCs (>40% suggestive), RBC casts (pathognomonic of GN), WBC casts, variable proteinuria.
  • CKD: "Bland" sediment (unless IgA/Lupus). Broad waxy casts (indicates dilated tubules/stasis), isosthenuria (inability to concentrate urine).
• Chemistry:
  • Creatinine: Daily doubling suggests ATN or severe RPGN; slow drift suggests CKD.
• Serology (Urgent for RPGN suspicion):
  • ANA, dsDNA (Lupus).
  • ANCA (MPO, PR3).
  • Anti-GBM antibodies.
  • Complements (C3/C4): Low in Lupus, Cryoglobulinemia, Infection-associated GN. Normal in Pauci-immune.
  • Cryoglobulins, Hepatitis B/C, HIV.

Imaging

• Renal Ultrasound (Key Differentiator):
  • RPGN: Kidneys are Normal size or Enlarged (swollen). Corticomedullary differentiation is preserved or edematous.
  • CKD: Kidneys are predominantly Small (<9 cm), Echogenic (bright due to fibrosis), with Cortical thinning.
  • Exception: Diabetic nephropathy, HIV nephropathy, and Amyloidosis can present with normal/large kidneys even in CKD.

Procedures

• Renal Biopsy:
  • RPGN: Mandatory and urgent (within 24 hours if possible) to confirm crescents and guide immunosuppression intensity.
  • CKD: Usually not indicated if kidneys are typically small/echogenic (risk of bleeding > benefit; tissue often shows irreversible sclerosis).

Management

Acute Management (Suspected RPGN)

• Immediate: Stop potential nephrotoxins. Control hypertensive urgency (~140-160 mmHg systolic target typically safe, depending on cerebral perfusion).
• Empiric Therapy: If serology is pending but high suspicion of vasculitis/Anti-GBM:
  • Pulse Steroids: Methylprednisolone 500 mg–1000 mg IV daily x 3 days.
• Plasmapheresis (PLEX): Indicated for Anti-GBM disease and severe ANCA vasculitis (creatinine >5.7 mg/dL or pulmonary hemorrhage).

Treatment Algorithms

RPGN (Induction Phase)

1. Corticosteroids: Pulse IV followed by high-dose oral prednisone (1 mg/kg/day) with taper.
2. Cyclophosphamide: IV pulse (e.g., EUVAS or CYCLOPS protocol) or Oral.
   • OR Rituximab: 375 mg/m² x 4 weeks or 1g x 2 doses (RAVE trial data shows non-inferiority for ANCA).
3. Avacopan: C5a receptor inhibitor (adjunct in ANCA vasculitis to spare steroids).

CKD (Chronic Care Model)

1. First-Line (Prognostic Modifying):
   • ACEi or ARB: Titrate to max tolerated dose for proteinuria/HTN.
   • SGLT2 Inhibitors: (e.g., Dapagliflozin, Empagliflozin) for CKD with/without diabetes (GFR >20).
2. Second-Line:
   • Finerenone: Non-steroidal MRA for T2DM with CKD.
   • Statins: Atorvastatin/Rosuvastatin (Cardiovascular risk reduction).
3. Metabolic Management:
   • Phosphate binders, Calcitriol/calcimimetics (for secondary hyperparathyroidism).
   • Erythropoiesis-Stimulating Agents (ESA) for Hb <10 g/dL (after iron repletion).
   • Bicarbonate for metabolic acidosis (Target bicarb 22-26 mmol/L).

Complications

System	RPGN (Acute Complications)	CKD (Chronic Complications)
Cardiovascular	Acute pulmonary edema, hypertensive crisis	#1 Cause of death: MI, Heart Failure, LVH
Hematologic	Thrombocytopenia (TMA), DIC	Anemia of chronic disease, platelet dysfunction
Electrolyte	Rapid severe hyperkalemia, tumor lysis	Chronic hyperkalemia, hyperphosphatemia
Infectious	Opportunistic infections (PCP/PJP) from Rx	Impaired immunity, catheter infections
Bone	N/A (too acute)	CKD-MBD (Renal osteodystrophy)

Prognosis

• RPGN:
  • Dependent on percentage of cellular vs. fibrous crescents on biopsy.
  • Cellular crescents: Reversible with therapy.
  • Fibrous crescents: Irreversible.
  • Without treatment: >90% progress to ESKD/Death quickly.
  • With treatment: 70-80% renal survival at 1 year (ANCA), but relapse risk exists.
• CKD:
  • Calculated via Kidney Failure Risk Equation (KFRE) (takes age, sex, GFR, albuminuria).
  • Progressive decline. High mortality from cardiovascular events before reaching ESKD.

Prevention

• Primary: Difficult for RPGN (autoimmune). Control DM/HTN for CKD.
• Secondary:
  • RPGN: Maintenance immunosuppression (Azathioprine, Rituximab every 6mo) to prevent relapse.
  • CKD: Avoid NSAIDs, iodinated contrast (if dehydrated), aminoglycosides.
• Tertiary: Renal Replacement Therapy (Dialysis/Transplant).

Special Populations

• Pediatric:
  • RPGN: Post-streptococcal GN is the commonest cause; prognosis usually better than adults.
  • CKD: CAKUT (Congenital Anomalies of Kidney and Urinary Tract) is the leading cause. Growth retardation is a major complication (needs aggressive nutritional support/Growth Hormone).
• Geriatric:
  • High incidence of ANCA vasculitis.
  • High risk of infection with cyclophosphamide (consider dose reduction or Rituximab).
  • CKD is often overdiagnosed due to physiologic GFR decline; distinguish "disease" from "senescence."
• Pregnancy:
  • Active Lupus Nephritis (RPGN types) is high risk for fetal loss/preeclampsia.
  • CKD: High risk of progression if Creatinine >1.4 mg/dL at conception.

Clinical Pearls

1. The "Active Sediment" Rule: If Creatinine is elevated, spin the urine. If you see RBC casts or >40% dysmorphic RBCs, assume RPGN until proven otherwise. Do not attribute to "dehydration" or "UTI".
2. Kidney Size: The most reliable rapid imaging clue. Small kidneys = CKD. Normal/Large kidneys = Acute process (RPGN, ATN, or infiltration).
3. Pulmonary-Renal Syndrome: Any patient with acute kidney failure and hemoptysis (or unexplained alveolar infiltrates) has Anti-GBM or Vasculitis until proven otherwise.
4. No Contrast: Do not delay CT chest for pulmonary embolism/hemorrhage fear of contrast nephropathy in suspected RPGN. The lungs will kill the patient faster than the dye hurts the kidneys.

Recent Updates

• PEXIVAS Trial (2020): Reduced indications for plasma exchange in ANCA vasculitis (did not reduce ESKD/death in general severe population), though still considered for significant pulmonary hemorrhage.
• Avacopan (ADVOCATE Trial): FDA approved (2021) for ANCA vasculitis; showed non-inferiority to prednisone taper and better renal recovery in some subsets.
• SGLT2 inhibitors: Now Class 1A recommendation for CKD (diabetic and non-diabetic etiologies) to slow progression.
• EMPA-KIDNEY (2022): Demonstrated benefit of Empagliflozin in patients with CKD even without diabetes.

Key References

• Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
• Guideline: KDIGO 2024 Clinical Practice Guideline for the Management of Glomerular Diseases (ANCA, Lupus, Anti-GBM sections).
• Study: Walsh M et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis (PEXIVAS). N Engl J Med. 2020.
• Study: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis (ADVOCATE). N Engl J Med. 2021.
• Review: Kitching AR et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020.